Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$0.38 - $0.76 $6,764 - $13,528
-17,800 Reduced 23.03%
59,499 $24,000
Q2 2023

Aug 11, 2023

SELL
$0.68 - $12.39 $62,968 - $1.15 Million
-92,600 Reduced 54.5%
77,299 $53,000
Q1 2023

May 12, 2023

SELL
$0.9 - $7.89 $1,710 - $14,991
-1,900 Reduced 1.11%
169,899 $1.34 Million
Q4 2022

Feb 13, 2023

SELL
$0.67 - $1.2 $16,342 - $29,270
-24,392 Reduced 12.43%
171,799 $155,000
Q3 2022

Nov 14, 2022

SELL
$0.96 - $1.69 $12,679 - $22,321
-13,208 Reduced 6.31%
196,191 $214,000
Q2 2022

Aug 12, 2022

BUY
$0.85 - $2.36 $20,485 - $56,876
24,100 Added 13.01%
209,399 $258,000
Q1 2022

May 13, 2022

BUY
$1.82 - $3.24 $11,648 - $20,736
6,400 Added 3.58%
185,299 $437,000
Q4 2021

Feb 11, 2022

SELL
$2.36 - $4.05 $53,824 - $92,368
-22,807 Reduced 11.31%
178,899 $555,000
Q3 2021

Nov 12, 2021

SELL
$3.75 - $4.86 $207,622 - $269,078
-55,366 Reduced 21.54%
201,706 $819,000
Q2 2021

Aug 13, 2021

BUY
$3.83 - $5.65 $89,135 - $131,492
23,273 Added 9.95%
257,072 $1.24 Million
Q1 2021

May 13, 2021

BUY
$5.07 - $8.27 $98,865 - $161,265
19,500 Added 9.1%
233,799 $1.21 Million
Q4 2020

Feb 10, 2021

SELL
$6.12 - $10.37 $208,153 - $352,704
-34,012 Reduced 13.7%
214,299 $1.43 Million
Q3 2020

Nov 13, 2020

SELL
$9.27 - $13.79 $461,646 - $686,742
-49,800 Reduced 16.71%
248,311 $2.53 Million
Q2 2020

Aug 13, 2020

BUY
$9.43 - $20.28 $1.4 Million - $3.02 Million
148,930 Added 99.83%
298,111 $3.74 Million
Q1 2020

May 14, 2020

BUY
$3.39 - $18.0 $505,723 - $2.69 Million
149,181 New
149,181 $1.64 Million

Others Institutions Holding BLPH

# of Institutions
1
Shares Held
44K
Call Options Held
0
Put Options Held
0

About Bellerophon Therapeutics, Inc.


  • Ticker BLPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,545,450
  • Market Cap $382K
  • Description
  • Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development...
More about BLPH
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.